SINGAPORE — A two-drug HIV therapy that GlaxoSmithKline hopes can be delivered via a single pill is a candidate to enter China’s fast-track review process — making it a rare, and potentially lucrative, example of a cutting-edge therapy reaching emerging markets.

Both drugs in the combo therapy — Tivicay and Complera — are already approved and manufactured in China. The combination showed strong results in recent Phase III clinical trials, performing as well as three- and four-drug cocktails. GSK hopes the two-drug regimen will have fewer side effects for HIV patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy